# Phase 1 Diabetes Mellitus, Type 2 trials: 44 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 44 trials in phase 1 for Diabetes Mellitus, Type 2 that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Diabetes Mellitus, Type 2 trials: 44 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/diabetes-mellitus-type-2

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 44
- Recruiting or not yet: 44
- Read on: November 19, 2026

## Trials

The 25 newest of 44, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944118 | Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in... | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Overweight, Obesity, Type 2 Diabetes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944118) |
| October 26, 2026 | NCT07896109 | A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes | Novo Nordisk A/S | Phase 1 | Recruiting | Diabetes Mellitus, Type 2 | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896109) |
| October 20, 2026 | NCT07881887 | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 617 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881887) |
| October 15, 2026 | NCT07877038 | Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Not yet recruiting | Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877038) |
| October 9, 2026 | NCT07868354 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868354) |
| October 2, 2026 | NCT07855133 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855133) |
| September 25, 2026 | NCT07841860 | A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose... | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Weight Management, Type 2 Diabetes | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841860) |
| September 8, 2026 | NCT07807059 | A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807059) |
| September 4, 2026 | NCT07803809 | Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Recruiting | Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803809) |
| August 31, 2026 | NCT07794254 | A Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 2 Diabetes Mellitus | Hangzhou Reprogenix Bioscience, Inc | Phase 1 | Not yet recruiting | Diabete Mellitus, Diabete Type 2 | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794254) |
| August 21, 2026 | NCT07778524 | Alpelisib Challenge Test (ACT) | Columbia University | Phase 1 | Recruiting | Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778524) |
| July 28, 2026 | NCT07730567 | A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B | Addpharma Inc. | Phase 1 | Not yet recruiting | Hyperlipidemia, Diabete Type 2 | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730567) |
| July 23, 2026 | NCT07723833 | A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants | AstraZeneca | Phase 1 | Recruiting | Healthy Participants | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723833) |
| June 5, 2026 | NCT07630233 | A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy... | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Recruiting | Type 2 Diabetes Mellitus (T2DM) | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630233) |
| May 15, 2026 | NCT07590466 | A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian... | Autotelicbio | Phase 1 | Not yet recruiting | Diabete Type 2, Hypertension | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590466) |
| May 15, 2026 | NCT07590193 | A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus | Amgen | Phase 1 | Recruiting | Diabetes Mellitus, Type 2 | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590193) |
| May 14, 2026 | NCT07588503 | FES Cycling With BFR in the Spinal Cord Injury Population | Sponsor not shown (see the record) | Phase 1 | Recruiting | Spinal Cord Injury, Cardio Vascular Disease, Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588503) |
| May 6, 2026 | NCT07570992 | A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM | Novo Nordisk A/S | Phase 1 | Recruiting | Healthy Volunteers, Diabetes Mellitus, Type 2 | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570992) |
| May 6, 2026 | NCT07568678 | A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes | Hua Medicine Limited | Phase 1 | Recruiting | Type 2 Diabetes | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07568678) |
| April 23, 2026 | NCT07548957 | A Study to Evaluate the Safety and Pharmacokinetics of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy... | Korea United Pharm. Inc. | Phase 1 | Not yet recruiting | Diabetes Mellitus (Type 2) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548957) |
| April 20, 2026 | NCT07539415 | A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult... | Daewoong Pharmaceutical Co. LTD. | Phase 1 | Recruiting | Obesity & Overweight, Type 2 Diabetes | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539415) |
| April 8, 2026 | NCT07518121 | A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Phase 1 | Not yet recruiting | Diabete Type 2 | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518121) |
| March 18, 2026 | NCT07479862 | A Study of SA030 Injection in Overweight/Obese Participants With or Without Type 2 Diabetes Mellitus (T2DM) | Suzhou Siran Biotechnology Co.,Ltd. | Phase 1 | Recruiting | Obese, Overweight, T2DM (Type 2 Diabetes Mellitus) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07479862) |
| March 11, 2026 | NCT07463196 | A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in... | AC Immune SA | Phase 1 | Recruiting | Healthy Participants, Obesity, Type 2 Diabetes Mellitus (T2DM) | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463196) |
| February 4, 2026 | NCT07385547 | Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency | Sun Pharmaceutical Industries Limited | Phase 1 | Recruiting | Type II Diabetes Mellitus | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07385547) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 6 |
| [Fujian Shengdi Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/fujian-shengdi-pharmaceutical-co-ltd) | 3 |
| The University of Texas Health Science Center at San Antonio | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| University of California, San Diego | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| Biolexis Therapeutics | 1 |
| [Gan & Lee Pharmaceuticals.](https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals) | 1 |
| [Shanghai Minwei Biotechnology Co., Ltd](https://specstream.ai/data/clinical-trials/company/shanghai-minwei-biotechnology-co-ltd) | 1 |
| University of Maryland, Baltimore | 1 |
| Suzhou Siran Biotechnology Co.,Ltd. | 1 |
| AC Immune SA | 1 |
| AdipoPharma LLC | 1 |
| [Daewoong Pharmaceutical Co. LTD.](https://specstream.ai/data/clinical-trials/company/daewoong-pharmaceutical-co-ltd) | 1 |
| Nimble Science Ltd. | 1 |
| Hangzhou Reprogenix Bioscience, Inc | 1 |
| Regend Therapeutics | 1 |
| 1Globe Health Institute | 1 |
| [Korea United Pharm. Inc.](https://specstream.ai/data/clinical-trials/company/korea-united-pharm-inc) | 1 |
| Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 1 |
| Montreal Heart Institute | 1 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 1 |
| [Sun Pharmaceutical Industries Limited](https://specstream.ai/data/clinical-trials/company/sun-pharmaceutical-industries-limited) | 1 |
| [Gan and Lee Pharmaceuticals, USA](https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals-usa) | 1 |
| Hua Medicine Limited | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 17 |
| China | 9 |
| Germany | 4 |
| Canada | 4 |
| South Korea | 3 |
| Australia | 2 |
| Netherlands | 1 |
| Brazil | 1 |
| Singapore | 1 |
| Austria | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Taiwanese restaurants in the United States](https://specstream.ai/data/businesses/taiwanese-restaurants/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
- [Web design firms in the United States](https://specstream.ai/data/businesses/web-design-firms/united-states)
- [Accounting firms in the United States](https://specstream.ai/data/businesses/accounting-firms/united-states)
- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
